TJ0113

Phase 2Small molecule

HHangzhou PhecdaMed Co., Ltd.

TJ0113 is one of 93 small molecule programs targeting Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Depressive DisorderActive, not recruiting

Hearing LossActive, not recruiting

Depressive DisorderPhase 2

Active, not recruiting

Hearing LossPreclinical

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Depressive Disorder

#DrugCompanyPhaseTrials

Elavil

Voltaren

Intropin

Lexapro

Tofranil

Estrace

Vyvanse

Rozerem

Brintellix

Namenda

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Depressive Disorder

NCT07018245

Q2 2027

N/ANot yet recruiting

Hearing Loss

NCT07012746

Clinical

Trials by Indication[1]

Depressive Disorder1 trial

Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder

Recruiting·HHangzhou PhecdaMed Co., Ltd.·Phase 2·NCT07018245·150 enrolled

Parkinson's Disease1 trial

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06596005·149 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects

Completed·HHangzhou PhecdaMed Co., Ltd.·Phase 1·NCT07394452·130 enrolled

Hearing Loss1 trial

A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss

Not yet recruiting·YYilai Shu·N/A·NCT07012746·60 enrolled

Unspecified1 trial

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

Completed·HHangzhou PhecdaMed Co., Ltd.·Phase 1·NCT06832540·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TJ0113. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TJ0113 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TJ0113. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou PhecdaMed Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHangzhou PhecdaMed Co., Ltd.

TJ0113

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Trials by Indication[1]

Depressive Disorder1 trial

Parkinson's Disease1 trial

Single Ascending Dose1 trial

Hearing Loss1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News